Atrial Flutter

01Pathophysiology

Atrial flutter is a macro-reentrant tachyarrhythmia confined to the atrium. Unlike atrial fibrillation, which involves chaotic and disorganized electrical activity across the atria, atrial flutter follows a single, organized, self-perpetuating electrical circuit.

In typical (type I) atrial flutter, the reentrant circuit travels through the right atrium in a counterclockwise direction (when viewed from the tricuspid annulus). The circuit travels up the interatrial septum, across the roof of the right atrium, down the right atrial free wall, and then through a narrow corridor of tissue between the tricuspid valve annulus and the inferior vena cava known as the cavotricuspid isthmus (CTI). This isthmus is the critical slow-conduction zone that sustains the circuit and is the target for catheter ablation.

The organized atrial depolarization produces a consistent atrial rate, typically around 300 beats per minute. The AV node cannot conduct every impulse at that rate, so it acts as a physiological gatekeeper. Most commonly, the AV node conducts every other impulse, resulting in a 2:1 conduction ratio and a ventricular rate of approximately 150 bpm. This is why a regular narrow-complex tachycardia at 150 bpm should immediately raise suspicion for atrial flutter with 2:1 block. Other conduction ratios (3:1, 4:1, or variable block) are also possible, particularly when AV-nodal blocking agents are on board.

The hemodynamic consequences stem from two problems. First, the rapid ventricular rate reduces diastolic filling time, which lowers cardiac output. Second, the loss of coordinated atrial contraction ("atrial kick") further compromises ventricular preload, which is particularly harmful in patients with diastolic dysfunction or valvular disease. Over time, sustained rapid rates can lead to tachycardia-induced cardiomyopathy, a reversible form of heart failure that resolves once the rate or rhythm is controlled.

The stasis of blood in the atria creates a prothrombotic environment, placing these patients at risk for thromboembolic events including stroke. The stroke risk in atrial flutter is managed identically to atrial fibrillation using the $CH{A}_{2}D{S}_2\text{-}VAScCHA\_2DS\_2\backslash text\{-\}VASc$ scoring system.

02Classification and Clinical Manifestation

Classification

Clinical Manifestation by Presentation

03Diagnostic Workup

The best initial test is a 12-lead ECG. The hallmark finding is the sawtooth pattern of flutter waves (F waves), which appear as a continuous, undulating baseline without a flat isoelectric interval between deflections. These are best visualized in the inferior leads (II, III, aVF) and in V1. In typical counterclockwise flutter, the F waves are inverted (negative) in the inferior leads and upright (positive) in V1.

A common exam scenario presents a regular narrow-complex tachycardia at exactly 150 bpm, and the flutter waves are hidden within the QRS complexes or T waves. The next best step in this situation is to perform vagal maneuvers (carotid sinus massage or Valsalva) or administer intravenous adenosine. These interventions transiently slow AV conduction, which unmasks the underlying flutter waves. This is a critical teaching point: adenosine will reveal the diagnosis but will not convert flutter to sinus rhythm. If the vignette describes a tachycardia at 150 bpm that "slows to reveal a sawtooth pattern" after adenosine, the answer is atrial flutter.

Transthoracic echocardiography (TTE) should be obtained to assess left ventricular ejection fraction, valvular pathology, and atrial dimensions. This information guides both acute management and long-term decisions about anticoagulation and ablation candidacy.

If cardioversion is planned and the duration of flutter exceeds 48 hours or is unknown, a transesophageal echocardiogram (TEE) is required to exclude a left atrial appendage thrombus before proceeding. Alternatively, the patient can be anticoagulated for at least 3 weeks before elective cardioversion.

Thyroid function tests and a basic metabolic panel should be checked to identify reversible contributors.

An electrophysiology (EP) study provides definitive circuit mapping and is the gold standard for confirming the mechanism. In practice, it is almost always coupled with catheter ablation in the same procedure.

04Management and Treatment

Step 1: Assess hemodynamic stability. If the patient is hemodynamically unstable (hypotension, altered mental status, acute pulmonary edema, or ongoing chest pain), the next best step is immediate synchronized DC cardioversion starting at 50 to 100 joules using a biphasic defibrillator. Do not delay cardioversion to obtain a TEE in an unstable patient. Anticoagulation should be initiated as soon as possible but should not delay the procedure.

Step 2: Rate control in the stable patient. For hemodynamically stable patients, the initial goal is to slow the ventricular rate below 110 bpm at rest. IV metoprolol or IV diltiazem are the preferred agents. Avoid using AV-nodal blockers (beta-blockers, calcium channel blockers, digoxin) as monotherapy in patients with Wolff-Parkinson-White syndrome, as slowing conduction through the AV node may paradoxically accelerate conduction through the accessory pathway.

An important clinical nuance: atrial flutter is often more resistant to rate control than atrial fibrillation. Because the atrial rate is fixed and regular, the AV node tends to conduct in fixed ratios. Pharmacologic rate control may shift conduction from 2:1 to 4:1 abruptly, producing sudden changes in heart rate rather than a smooth slowing. This relative difficulty in achieving rate control is one reason why rhythm control and ablation are favored earlier in flutter compared to atrial fibrillation.

Step 3: Consider rhythm control. Pharmacologic cardioversion can be attempted with ibutilide (a class III antiarrhythmic given intravenously). It is the most effective drug for acute conversion of atrial flutter but carries a risk of QT prolongation and torsades de pointes; patients must be monitored on telemetry for at least 4 to 6 hours after administration. Dofetilide is an alternative that can be used for both acute conversion and maintenance, but it requires initiation in an inpatient setting with serial QTc monitoring and renal dose adjustment. Amiodarone is less effective for acute conversion of flutter but may be used in patients with reduced ejection fraction where other antiarrhythmics are contraindicated.

Step 4: Catheter ablation. For recurrent or persistent typical atrial flutter, radiofrequency catheter ablation of the cavotricuspid isthmus is the definitive treatment and is considered first-line therapy. The procedure has a success rate exceeding 95% with a low complication rate. It is particularly favored over long-term antiarrhythmic drug therapy because of its high cure rate and the avoidance of drug side effects. If a vignette describes a patient with recurrent episodes of typical flutter despite rate control, ablation is the next best step.

Step 5: Anticoagulation. The thromboembolic risk in atrial flutter is managed using the same framework as atrial fibrillation. The $CH{A}_{2}D{S}_2\text{-}VAScCHA\_2DS\_2\backslash text\{-\}VASc$ score determines the need for long-term anticoagulation:

Direct oral anticoagulants (DOACs) such as apixaban, rivarelbaban, edoxaban, or dabigatran are preferred over warfarin for most patients due to fewer drug interactions, no need for INR monitoring, and a lower risk of intracranial hemorrhage. Warfarin remains preferred in patients with moderate-to-severe mitral stenosis or a mechanical heart valve.

Anticoagulation should continue even after successful ablation for a minimum of 2 months, and long-term decisions about continuation should be based on the $CH{A}_{2}D{S}_2\text{-}VAScCHA\_2DS\_2\backslash text\{-\}VASc$ score rather than on the success of the ablation itself.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students miss atrial flutter on the exam is by failing to recognize it when the ventricular rate is exactly 150 bpm. With a 2:1 conduction ratio, every other flutter wave is buried inside the QRS complex or the T wave, making the ECG look deceptively like sinus tachycardia or another SVT. The teaching rule is absolute: any regular narrow-complex tachycardia at 150 bpm is atrial flutter until proven otherwise.

A second classic trap involves the use of adenosine. Students who see the arrhythmia "slow down" after adenosine may incorrectly conclude that the arrhythmia was AVNRT and that adenosine "treated" it. The key distinction is that adenosine terminates AVNRT (the arrhythmia stops and sinus rhythm returns) but only unmasks atrial flutter (the sawtooth waves become visible transiently while the AV block increases, and then the tachycardia returns to its original rate once the adenosine wears off).

A third trap targets rate control. Students may try to manage atrial flutter with rate-controlling drugs alone indefinitely. While this works well for many atrial fibrillation patients, flutter is notoriously harder to rate-control pharmacologically. The tested concept is recognizing when to escalate to catheter ablation, which offers a near-curative success rate and is the preferred long-term strategy for recurrent typical flutter.

Finally, students sometimes forget that atrial flutter carries the same stroke risk as atrial fibrillation. A vignette that describes a patient with "only flutter" and asks about anticoagulation is testing whether you apply the $CH{A}_{2}D{S}_2\text{-}VAScCHA\_2DS\_2\backslash text\{-\}VASc$ score identically. The answer is yes: anticoagulate flutter patients exactly the same way you would anticoagulate atrial fibrillation patients.

The core competencies being tested with atrial flutter questions are: (1) pattern recognition of the sawtooth ECG and the 150 bpm clue, (2) understanding the diagnostic (not therapeutic) role of adenosine, (3) knowing when to escalate from rate control to ablation, and (4) applying anticoagulation guidelines uniformly across both atrial flutter and atrial fibrillation.